114 related articles for article (PubMed ID: 26414098)
1. Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease.
Gorniak P; Budziszewska B; Pula B; Wasylecka M; Borg K; Nowak G; Makuch-Lasica H; Lech-Maranda E; Warzocha K; Juszczynski P
Leuk Lymphoma; 2016; 57(6):1471-3. PubMed ID: 26414098
[No Abstract] [Full Text] [Related]
2. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation.
Sampath D; Calin GA; Puduvalli VK; Gopisetty G; Taccioli C; Liu CG; Ewald B; Liu C; Keating MJ; Plunkett W
Blood; 2009 Apr; 113(16):3744-53. PubMed ID: 19096009
[TBL] [Abstract][Full Text] [Related]
3. Role of
Rampazzo E; Bojnik E; Trentin L; Bonaldi L; Del Bianco P; Frezzato F; Visentin A; Facco M; Semenzato G; De Rossi A
Haematologica; 2017 Jul; 102(7):e253-e256. PubMed ID: 28385779
[No Abstract] [Full Text] [Related]
4. The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia.
Wang C; Wang X
Int J Clin Exp Pathol; 2013; 6(7):1223-9. PubMed ID: 23826404
[TBL] [Abstract][Full Text] [Related]
5. p53 protein expression in chronic lymphocytic leukemia.
Sellmann L; Carpinteiro A; Nückel H; Scholtysik R; Siemer D; Klein-Hipass L; Kube D; Dürig J; Dührsen U; Stanelle J; Küppers R
Leuk Lymphoma; 2012 Jul; 53(7):1282-8. PubMed ID: 22220854
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.
Carrà G; Panuzzo C; Torti D; Parvis G; Crivellaro S; Familiari U; Volante M; Morena D; Lingua MF; Brancaccio M; Guerrasio A; Pandolfi PP; Saglio G; Taulli R; Morotti A
Oncotarget; 2017 May; 8(22):35508-35522. PubMed ID: 28418900
[TBL] [Abstract][Full Text] [Related]
7. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
8. The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.
Dal Bo M; D'Agaro T; Gobessi S; Zucchetto A; Dereani S; Rossi D; Zaja F; Pozzato G; Di Raimondo F; Gaidano G; Laurenti L; Del Poeta G; Efremov DG; Gattei V; Bomben R
Oncotarget; 2015 Aug; 6(22):19102-17. PubMed ID: 26036258
[TBL] [Abstract][Full Text] [Related]
9. Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach.
Te Raa GD; Malčiková J; Mraz M; Trbusek M; Le Garff-Tavernier M; Merle-Béral H; Greil R; Merkel O; Pospíšilová S; Lin K; Pettitt AR; Stankovic T; van Oers MH; Eldering E; Stilgenbauer S; Zenz T; Kater AP;
Br J Haematol; 2014 Nov; 167(4):565-9. PubMed ID: 24975017
[No Abstract] [Full Text] [Related]
10. Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.
te Raa GD; Moerland PD; Leeksma AC; Derks IA; Yigittop H; Laddach N; Loden-van Straaten M; Navrkalova V; Trbusek M; Luijks DM; Zenz T; Skowronska A; Hoogendoorn M; Stankovic T; van Oers MH; Eldering E; Kater AP
Cell Death Dis; 2015 Aug; 6(8):e1852. PubMed ID: 26247737
[TBL] [Abstract][Full Text] [Related]
11. The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.
Boysen J; Sinha S; Price-Troska T; Warner SL; Bearss DJ; Viswanatha D; Shanafelt TD; Kay NE; Ghosh AK
Leukemia; 2014 Feb; 28(2):451-5. PubMed ID: 24217154
[No Abstract] [Full Text] [Related]
12. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
Chang H; Jiang AM; Qi CX
Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
14. Elevated
Bravo-Navas S; Yáñez L; Romón Í; Pipaón C
FASEB J; 2019 Sep; 33(9):10477-10489. PubMed ID: 31251079
[TBL] [Abstract][Full Text] [Related]
15. Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia.
de Viron E; Michaux L; Put N; Bontemps F; Van Den Neste E
Leuk Lymphoma; 2012 Aug; 53(8):1445-51. PubMed ID: 22280536
[TBL] [Abstract][Full Text] [Related]
16. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
Lin K; Rockliffe N; Johnson GG; Sherrington PD; Pettitt AR
Oncogene; 2008 Apr; 27(17):2445-55. PubMed ID: 17982489
[TBL] [Abstract][Full Text] [Related]
17. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.
Malcikova J; Stano-Kozubik K; Tichy B; Kantorova B; Pavlova S; Tom N; Radova L; Smardova J; Pardy F; Doubek M; Brychtova Y; Mraz M; Plevova K; Diviskova E; Oltova A; Mayer J; Pospisilova S; Trbusek M
Leukemia; 2015 Apr; 29(4):877-85. PubMed ID: 25287991
[TBL] [Abstract][Full Text] [Related]
18. The Janus Face of p53-Targeting Ubiquitin Ligases.
Hao Q; Chen Y; Zhou X
Cells; 2020 Jul; 9(7):. PubMed ID: 32660118
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
Dufour A; Palermo G; Zellmeier E; Mellert G; Duchateau-Nguyen G; Schneider S; Benthaus T; Kakadia PM; Spiekermann K; Hiddemann W; Braess J; Truong S; Patten N; Wu L; Lohmann S; Dornan D; GuhaThakurta D; Yeh RF; Salogub G; Solal-Celigny P; Dmoszynska A; Robak T; Montillo M; Catalano J; Geisler CH; Weisser M; Bohlander SK
Blood; 2013 May; 121(18):3650-7. PubMed ID: 23525797
[TBL] [Abstract][Full Text] [Related]
20. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
